Literature DB >> 31338528

[Pheochromocytoma and paraganglioma : Importance of diagnostic imaging].

W G Kunz1, C J Auernhammer2, S Nölting2, T Pfluger3, J Ricke4, C C Cyran4.   

Abstract

CLINICAL
BACKGROUND: If pheochromocytoma (PC) or paraganglioma (PGL) is diagnosed based on serologic studies, imaging is required to locate the adrenal mass for further management. Besides pathognomonic hormonal findings, PC/PGL can exhibit typical imaging features. However, PC/PGL can also show morphological overlap with other pathologies. STANDARD RADIOLOGICAL
METHODS: The modality of choice for evaluation of PC is CT. In case of extra-adrenal location, MRI is superior to CT. Imaging with PET-CT provides complementary information in the differentiation of PC/PGL and is recommended as the imaging modality of choice for malignant PC/PGL. 68Ga-DOTATATE (or 68Ga-DOTATOC/ 68Ga-DOTANOC) PET-CT has high sensitivity for SDHx-mutated PC/PGL and serves for planning of radioreceptor therapy with somatostatin analogues. In contrast, 123I-metaiodobenzylguanidine (MIBG) scintigraphy is important in assessing the potential efficacy of radioreceptor therapy with MIBG. METHODICAL DETAILS: The CT protocol for PC evaluation should include non-enhanced, arterial, portal-venous and late phases; the latter for the evaluation of wash-out. Recent studies indicate non-enhanced CT alone may be sufficient to rule out PC. For MRI, in- and opposed-phase sequences should be additionally acquired. PRACTICAL RECOMMENDATIONS: A relevant proportion of PC is diagnosed incidentally. Therefore, imaging of PC will gain further importance. Recent studies show better response rates of PC/PGL after radioreceptor therapy with somatostatin analogues (177Lu-DOTATATE) than with MIBG. Therefore, 68Ga-DOTATATE PET-CT gains further importance-for diagnostic imaging and therapy planning.

Entities:  

Keywords:  Computed tomography; Diagnostic imaging; Neuroendocrine tumors; Positron-emission tomography; Somatostatin analogues

Mesh:

Year:  2019        PMID: 31338528     DOI: 10.1007/s00117-019-0569-7

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  26 in total

1.  Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.

Authors:  Ingo Janssen; Elise M Blanchet; Karen Adams; Clara C Chen; Corina M Millo; Peter Herscovitch; David Taieb; Electron Kebebew; Hendrik Lehnert; Antonio T Fojo; Karel Pacak
Journal:  Clin Cancer Res       Date:  2015-04-14       Impact factor: 12.531

2.  Surgical therapy of adrenal tumors: guidelines from the German Association of Endocrine Surgeons (CAEK).

Authors:  K Lorenz; P Langer; B Niederle; P Alesina; K Holzer; Ch Nies; Th Musholt; P E Goretzki; N Rayes; M Quinkler; J Waldmann; D Simon; A Trupka; R Ladurner; K Hallfeldt; A Zielke; D Saeger; Th Pöppel; G Kukuk; A Hötker; P Schabram; S Schopf; C Dotzenrath; P Riss; Th Steinmüller; I Kopp; C Vorländer; M K Walz; D K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2019-04-01       Impact factor: 3.445

3.  MDCT of adrenal masses: Can dual-phase enhancement patterns be used to differentiate adenoma and pheochromocytoma?

Authors:  Benjamin G Northcutt; Siva P Raman; Christopher Long; Alexander R Oshmyansky; Stanley S Siegelman; Elliot K Fishman; Pamela T Johnson
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

4.  Multimodality imaging findings of pheochromocytoma with associated clinical and biochemical features in 53 patients with histologically confirmed tumors.

Authors:  Asim Raja; Katherine Leung; Michael Stamm; Safwat Girgis; Gavin Low
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

5.  CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material.

Authors:  Richard Bessell-Browne; Martin E O'Malley
Journal:  AJR Am J Roentgenol       Date:  2007-04       Impact factor: 3.959

Review 6.  [Update on endocrine hypertension].

Authors:  B Lechner; D Heinrich; S Nölting; A Osswald-Kopp; G Rubinstein; J Sauerbeck; F Beuschlein; M Reincke
Journal:  Internist (Berl)       Date:  2018-11       Impact factor: 0.743

Review 7.  Pheochromocytoma: the range of appearances on ultrasound, CT, MRI, and functional imaging.

Authors:  Katherine Leung; Michael Stamm; Asim Raja; Gavin Low
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

8.  Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.

Authors:  Aurélien Archier; Arthur Varoquaux; Philippe Garrigue; Marion Montava; Carole Guerin; Sophie Gabriel; Eva Beschmout; Isabelle Morange; Nicolas Fakhry; Frédéric Castinetti; Frédéric Sebag; Anne Barlier; Anderson Loundou; Benjamin Guillet; Karel Pacak; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-05       Impact factor: 9.236

Review 9.  European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.

Authors:  P F Plouin; L Amar; O M Dekkers; M Fassnacht; A P Gimenez-Roqueplo; J W M Lenders; C Lussey-Lepoutre; O Steichen
Journal:  Eur J Endocrinol       Date:  2016-05       Impact factor: 6.664

10.  Missed clinical clues in patients with pheochromocytoma/paraganglioma discovered by imaging.

Authors:  Natalie Rogowski-Lehmann; Aikaterini Geroula; Aleksander Prejbisz; Henri J L M Timmers; Felix Megerle; Mercedes Robledo; Martin Fassnacht; Stephanie Fliedner; Martin Reincke; Anthony Stell; Andrzej Januszewicz; Jacques Lenders; Graeme Eisenhofer; Felix Beuschlein
Journal:  Endocr Connect       Date:  2018-09-01       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.